



National Cancer Institute

Hematopoietic and Lymphoid Neoplasm Project





Acknowledgments

- American College of Surgeons (ACOS) Commission on Cancer (COC)
- Canadian Cancer Registries (CCR)
- National Cancer Registrars Association (NCRA)
- National Program of Cancer Registries (NPCR) of the Centers for Disease Control (CDC)
- North American Association of Central Cancer Registries (NAACCR)





With Special Thanks to

- Graca Dores, MD
- Charles Platz, MD
- Amy Blum, RHIT, CTR
- The Hematopoietic Working Group





Grade of Tumor Rules

Peggy Adamo, RHIT, CTR

NCI SEER

October 2009



The Grade Field

- NAACCR Item #440: “Grade”
- Immunophenotype Designation for Lymphomas and Leukemias





Grade of Tumor Rules

- **Note 1:** Use the Grade of Tumor Rules (G1-G11) to assign the correct code in grade field
- **Note 2:** Do **not** use Table 13 on pages 16-17 of ICD-O-3 to determine grade





Rule G1


Code cell type not determined, not stated, not applicable (**code 9**) for the following myeloproliferative neoplasms, myeloproliferative/myelodysplastic syndromes, myelodysplastic syndrome, histiocytic and dendritic cell neoplasms





Rule G1 Continued

9740/3	9759/3	9962/3	9983/3
9741/3	9875/3	9963/3	9985/3
9742/3	9876/3	9964/3	9986/3
9751/3	9945/3	9975/3	9989/3
9755/3	9946/3	9980/3	9991/3
9757/3	9950/3	9982/3	9992/3
9758/3	9961/3	9982/3	





Rule G1 *Notes*

- **Note 1:** These neoplasms do not have a specific codable phenotype
- **Note 2:** See Tables B1, B3, B4, and B11 in Appendix B for neoplasm terms and codes






Appendix B

WHO Classification of Tumors of Hematopoietic and Lymphoid Tissues Histology Lineage

- Table B1: Myeloproliferative Neoplasms
- Table B3: Myelodysplastic / Myeloproliferative Neoplasms
- Table B4: Myelodysplastic Syndromes
- Table B11: Histiocytic and Dendritic Cell Neoplasms





Rule G2

Use statements from **any** part of the medical record including, but not limited to

- Pathology report **OR**
- History and physical **OR**
- Consultation **OR**
- Final diagnosis **OR**
- Face sheet





Rule G3

Use codes 5, 6, 7, 8, and/or 9 **only** --
even if there is a statement giving the cell type in
the medical record





Rule G3 *Notes*

- **Note 1:** Do **not** code descriptions “low grade,” “intermediate grade,” or “high grade” in the Tumor Grade field. These terms refer to the Working Formulation categories of lymphoma diagnosis
- **Note 2:** Do **not** code the descriptions “Grade 1,” “Grade 2,” or “Grade 3” in the Tumor Grade field. These grades represent histology types of lymphoma rather than differentiation





Rule G4

Code T-cell (code **5**) for the following neoplasms; **T-cell** is part of the neoplasm name or the neoplasm is of **T-cell origin**





Rule G4 Continued

9701/3	9716/3	9827/3
9702/3	9717/3	9831/3
9705/3	9718/3	9834/3
9708/3	9724/3	9837/3
9709/3	9725/3	
9714/3*	9726/3	

*(unless pathologist specifically designates as B-cell)





Rule G4 *Note 1*

- Record T-cell even though it is not mentioned as a specific phenotype in the pathology or other test report(s). Frequently physicians do not mention T-cell phenotype because they know the phenotype or they understand that the phenotype is inherent in the disease classification/name





Rule G4 *Note 2*

- When the medical record or pathology report contains one of these terms with a different phenotype (B-cell, null-cell, or NK-cell) check with the pathologist to determine whether the disease name is correctly recorded. It is possible that the mention of a different phenotype may be the result of the pathologist using a different disease classification





Rule G5

Code T-cell (code 5) when the neoplasm is identified as **T-cell, T-cell phenotype, T-precursor, Pre-T, gamma-delta-T, or null-cell T-cell**





Rule G6


Code B-cell (code 6) for the following **B-cell precursor lymphoid neoplasms** and the **mature B-cell neoplasms**





Rule G6 Continued

9591/3	9679/3	9691/3	9732/3	9813/3	9833/3
9596/3	9680/3	9695/3	9734/3	9814/3	9836/3
9597/3	9684/3	9698/3	9737/3	9815/3	9940/3
9670/3	9687/3	9699/3	9738/3	9816/3	
9671/3	9688/3	9712/3	9762/3	9817/3	
9673/3	9689/3	9728/3	9811/3	9818/3	
9678/3	9690/3	9731/3	9812/3	9823/3	





G6 Note 1

- Record B-cell even though it is not mentioned as a specific phenotype in the pathology or other test report(s). Frequently physicians do not mention B-cell phenotype because they know the phenotype or they understand that the phenotype is inherent in the disease classification/name





G6 Note 2


- When the medical record or pathology report contains one of these terms with a different phenotype (T-cell, null-cell, or NK-cell) check with the pathologist to determine whether the disease name is correctly recorded. It is possible that the mention of a different phenotype may be the result of the pathologist using a different disease classification





G6 Note 3

- See Tables B7 and B8 in Appendix B





Appendix B

WHO Classification of Tumors of Hematopoietic and Lymphoid Tissues Histology Lineage

- Table B7: Precursor Lymphoid Neoplasms
- Table B8: Mature B-Cell Neoplasms





Rule G7


Code B-cell (code **6**) when the disease is identified as **B-cell, B-cell phenotype, B-precursor, pre-B, or null-cell and B-cell**





Rule G8

Code Null cell, non-T non-B (code **7**) when the disease is described as **null cell, non-T non-B**, or **common cell**





Rule G9

Code **NK-cell** (natural killer cell) (code **8**) for the following neoplasms; NK-cell is a part of the **neoplasm's name**

- 9719/3
- 9948/3





Rule G9 *Note 1*

- Record NK-cell even though it is not mentioned as a specific phenotype in the pathology or other test report(s). Frequently physicians do not mention NK-cell phenotype because they know the phenotype or they understand that the phenotype is inherent in the disease classification/name





Rule G9 *Note 2*

- When the medical record or pathology report contains one of these terms with a different phenotype (B-cell, T-cell, or null-cell) check with the pathologist to determine whether the disease name is correctly recorded. It is possible that the mention of a different phenotype may be the result of the pathologist using a different disease classification





Rule G9 *Note 3*

- See Table B8 in Appendix B





Appendix B

WHO Classification of Tumors of Hematopoietic and Lymphoid Tissues Histology Lineage

- Table B8: Mature B-Cell Neoplasms





Rule G10

Code Natural Killer (NK) cell (code **8**) when the disease is described as **NK cell, natural killer cell, nasal NK/T-cell lymphoma, or null-cell and NK cell**





Rule G11

Code cell type not determined, not stated, not applicable (code 9) when

- There is **no statement describing the cell type OR**
- The cell type is described as **combined T AND B cell OR**
- The cell type is described as **combined B AND NK cell**





Rule G11 *Note*

- There is a new site-specific factor to collect combination cell types for hematopoietic or lymphatic neoplasms in the Collaborative Stage Data Collection System, Version 2





Conclusion

- The new Hematopoietic and Lymphoid Neoplasm Rules go into effect for cases diagnosed **January 1, 2010, and after**
- Email address for questions askseerctr@imsweb.com

